China Biologic Products, Inc. (CBPO) Given $131.67 Average Target Price by Analysts

Shares of China Biologic Products, Inc. (NASDAQ:CBPO) have been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus price target of $131.67 for the company and are anticipating that the company will post $1.30 EPS for the current quarter, according to Zacks. Zacks has also given China Biologic Products an industry rank of 154 out of 265 based on the ratings given to related companies.

Several brokerages have recently weighed in on CBPO. Zacks Investment Research cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Monday, August 7th. BidaskClub cut shares of China Biologic Products from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC reaffirmed a “buy” rating on shares of China Biologic Products in a research note on Friday, August 4th. Finally, Goldman Sachs Group, Inc. (The) began coverage on shares of China Biologic Products in a research note on Tuesday, May 30th. They set a “neutral” rating for the company.

COPYRIGHT VIOLATION WARNING: “China Biologic Products, Inc. (CBPO) Given $131.67 Average Target Price by Analysts” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/09/10/china-biologic-products-inc-cbpo-given-131-67-average-target-price-by-analysts.html.

Shares of China Biologic Products (NASDAQ:CBPO) traded up 1.74% on Friday, reaching $94.99. 320,624 shares of the company were exchanged. The stock has a 50 day moving average price of $94.61 and a 200-day moving average price of $104.58. China Biologic Products has a 12 month low of $88.25 and a 12 month high of $126.47. The stock has a market capitalization of $2.59 billion, a P/E ratio of 24.72 and a beta of 1.75.

China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.05. The company had revenue of $89.28 million during the quarter, compared to analysts’ expectations of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. During the same period last year, the business earned $1.26 EPS. On average, equities analysts expect that China Biologic Products will post $4.96 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of China Biologic Products by 694.1% during the 1st quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock worth $151,007,000 after acquiring an additional 1,318,183 shares in the last quarter. Jennison Associates LLC grew its stake in shares of China Biologic Products by 0.8% during the 2nd quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock worth $653,000 after acquiring an additional 44 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of China Biologic Products by 9.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 58,559 shares of the biopharmaceutical company’s stock worth $5,863,000 after acquiring an additional 5,091 shares in the last quarter. UBS Asset Management Americas Inc. grew its stake in shares of China Biologic Products by 9.3% during the 1st quarter. UBS Asset Management Americas Inc. now owns 198,220 shares of the biopharmaceutical company’s stock worth $19,848,000 after acquiring an additional 16,933 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in shares of China Biologic Products by 67.3% during the 1st quarter. Bank of America Corp DE now owns 56,118 shares of the biopharmaceutical company’s stock worth $5,619,000 after acquiring an additional 22,583 shares in the last quarter. 72.83% of the stock is owned by institutional investors.

China Biologic Products Company Profile

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply